AVP
In the context of the launch of its Late Stage Fund, AVP continues to strengthen its leadership team to reinforce its global platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502656787/en/
(Photo: Business Wire)
First, after the recruitment of Elizabeth de Saint-Aignan in the USA, Warda's appointment in Europe completes the senior team of the new AVP Late Stage Fund.
Prior to joining AVP, Warda Shaheen held the position of Director at OMERS Growth Equity, where she conducted investments in prominent software companies such as Coveo, TouchBistro, PandaDoc, Clio, Celigo and GitLab. Previously, Warda worked in public markets at CPP Investments where she ran a $500M public markets portfolio in the thematic investing team. She also worked at Point72 Asset Management, Bain & Company and Deutsche Bank. Warda has experience working in the United States, Canada, United Kingdom, Singapore, Hong Kong and Germany. Warda holds an MSc in Financial Economics from the University of Oxford, a BESc in Mechanical Engineering from the University of Western University and an HBA in Business Administration the Richard Ivey School of Business.
Second, Pedro's appointment as Partner in charge of investor relations underlines AVP's objective of managing more capital for top tier institutional investors. Pedro brings extensive experience in fundraising of technology funds, from his tenure at Target Global, where he played a key role in fundraising multiple tech funds and fostering investor relationships. He has also held senior positions at MVision and Hamilton Lane. Having started his career in the venture capital arm of FINEP, the Brazilian innovation agency, Pedro holds an MBA and a BSc in Industrial Engineering from Pontifícia Universidade Católica do Rio de Janeiro.
“On behalf of the AVP team, I am delighted to extend a warm welcome to Warda and Pedro as our newest Partners. I am also very proud that AVP can attract such talents, and in the case of Warda, convince top tier investor in the North American market to come to Paris. Warda will play a key role in developing our new Late Stage Fund strategy, focusing on Europe. With this new Late Stage fund, we now have the capability to support entrepreneurs throughout their journey, from the early stages to IPO, as well as post-IPO, which sets us apart in the market. Warda brings extensive knowledge and a proven track record in investing in Late Stage companies in the US and in Europe. In the context of our platform expansion and ongoing fundraising efforts across various strategies, we are very happy to benefit from Pedro’s substantial fundraising experience of technology focused fund. His background at Target Global will undoubtedly add value to the entire AVP platform. At AVP, nothing is more important than the quality, the diversity and the complementarity of the team. Since 8 years, we have welcomed 9 Partners and are now ready to further expand the team with these two talents. No doubt that they will play a key role in the next chapter of our journey," commented François Robinet, Managing Partner at AVP.
“I am thrilled to become a part of the outstanding team of investors at AVP. Since I was introduced to the firm, I recognized this platform had the vision, skills, and leadership to amplify the global landscape of technology investing with a diverse partnership that leverages expertise across the financing spectrum. AVP's Late Stage strategy in Europe addresses several challenges in the European ecosystem, including the shortage of local funding for exceptional European technology leaders to expand globally. At AVP, we look forward to bringing our collective knowledge to support such leaders at various stages in both the private and public markets,” commented Warda Shaheen, General Partner at AVP.
“I am excited to join an incredibly talented team of investor at AVP. I have been fortunate to follow the development of the platform over the years and, now as part of the team, look forward to develop their robust capital base to attract additional top tier institutional investors globally,” commented Pedro Barros, Partner at AVP.
About AVP (AXA Venture Partners)
AVP (AXA Venture Partners) is a global venture capital firm specializing in high-growth, technology- enabled companies, managing more than $2 billion in assets across four investment strategies: Venture, Growth, Late Stage, and Fund of Funds. Since its establishment in 2016, AVP has invested in more than 60 technology companies in Venture and Growth stages in the US and Europe.
With offices in New York, London, and Paris, AVP supports companies in expanding internationally and provides portfolio companies with tailored business development opportunities to further accelerate their growth. AVP operates under AXA IM- Alts, the alternative investment business unit of AXA IM.
For more information, visit axavp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502656787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
